| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Isvett J Flores-Sanchez, Huub J M Linthorst, Robert Verpoort. In silicio expression analysis of PKS genes isolated from Cannabis sativa L. Genetics and molecular biology. vol 33. issue 4. 2012-10-04. PMID:21637580. |
in silicio expression analysis of pks genes isolated from cannabis sativa l. cannabinoids, flavonoids, and stilbenoids have been identified in the annual dioecious plant cannabis sativa l. of these, the cannabinoids are the best known group of this plant's natural products. |
2012-10-04 |
2023-08-12 |
Not clear |
| F J Evan. Cannabinoids: the separation of central from peripheral effects on a structural basis. Planta medica. vol 57. issue 7 Suppl. 2012-10-02. PMID:17226225. |
a brief history of the therapeutic uses and legal problems of cannabis as well as the component cannabinoids is given. |
2012-10-02 |
2023-08-12 |
Not clear |
| G Fournier, M Pari. [Detection of Cannabinoids in Phelipaea ramosa, a Parasite of Cannabis sativa.]. Planta medica. vol 49. issue 12. 2012-10-02. PMID:17405065. |
[detection of cannabinoids in phelipaea ramosa, a parasite of cannabis sativa.]. |
2012-10-02 |
2023-08-12 |
Not clear |
| Yoshinari Shoyama, Chitomi Sugawa, Hiroyuki Tanaka, Satoshi Morimot. Cannabinoids act as necrosis-inducing factors in Cannabis sativa. Plant signaling & behavior. vol 3. issue 12. 2012-10-02. PMID:19704450. |
cannabinoids act as necrosis-inducing factors in cannabis sativa. |
2012-10-02 |
2023-08-12 |
Not clear |
| Yoshinari Shoyama, Chitomi Sugawa, Hiroyuki Tanaka, Satoshi Morimot. Cannabinoids act as necrosis-inducing factors in Cannabis sativa. Plant signaling & behavior. vol 3. issue 12. 2012-10-02. PMID:19704450. |
cannabis sativa is well known to produce unique secondary metabolites called cannabinoids. |
2012-10-02 |
2023-08-12 |
Not clear |
| Sabine Steffens, François Mac. Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. Future cardiology. vol 2. issue 1. 2012-10-02. PMID:19804131. |
cannabinoids, such as delta9-tetrahydrocannabinol (thc), which is the major psychoactive compound of marijuana, modulate immune functions and might therefore be of therapeutic use for the treatment of inflammatory diseases. |
2012-10-02 |
2023-08-12 |
mouse |
| Sabine Steffens, François Mac. Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. Future cardiology. vol 2. issue 1. 2012-10-02. PMID:19804131. |
however, these promising results are in conflict with the known health risks of smoking marijuana, as thc binds to and activates both cannabinoid receptors, cb(1) and cb(2). |
2012-10-02 |
2023-08-12 |
mouse |
| M Marselos, P Karamanako. Mutagenicity, developmental toxicity and carcinogenicity of cannabis. Addiction biology. vol 4. issue 1. 2012-10-02. PMID:20575764. |
concerning the developmental effects of cannabis, an increased embryolethality and somatic growth retardation have been observed in animals, as well as changes in motor behaviour, after perinatal exposure to cannabinoids. |
2012-10-02 |
2023-08-12 |
Not clear |
| M Marselos, P Karamanako. Mutagenicity, developmental toxicity and carcinogenicity of cannabis. Addiction biology. vol 4. issue 1. 2012-10-02. PMID:20575764. |
finally, the experimental work concerning the possible carcinogenic action of cannabinoids has shown that cannabis acts as a tumour promotor in animals. |
2012-10-02 |
2023-08-12 |
Not clear |
| Karl W Hillig, Paul G Mahlber. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). American journal of botany. vol 91. issue 6. 2012-10-02. PMID:21653452. |
a chemotaxonomic analysis of cannabinoid variation in cannabis (cannabaceae). |
2012-10-02 |
2023-08-12 |
Not clear |
| Karl W Hillig, Paul G Mahlber. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). American journal of botany. vol 91. issue 6. 2012-10-02. PMID:21653452. |
cannabinoids are important chemotaxonomic markers unique to cannabis. |
2012-10-02 |
2023-08-12 |
Not clear |
| Rudolf Schicho, Martin Stor. Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. Expert review of clinical pharmacology. vol 3. issue 2. 2012-10-02. PMID:22111567. |
cannabinoids extracted from the marijuana plant (cannabis sativa) and synthetic cannabinoids have numerous effects on gastrointestinal (gi) functions. |
2012-10-02 |
2023-08-12 |
Not clear |
| Eva de Lago, María Gómez-Ruiz, Miguel Moreno-Martet, Javier Fernández-Rui. Cannabinoids, multiple sclerosis and neuroprotection. Expert review of clinical pharmacology. vol 2. issue 6. 2012-10-02. PMID:22112258. |
in recent years, several laboratories have addressed the therapeutic potential of cannabinoids in ms, given the experience reported by some ms patients who self-medicated with marijuana. |
2012-10-02 |
2023-08-12 |
Not clear |
| F Taur. Studies on tetrahydrocannabinolic acid synthase that produces the acidic precursor of tetrahydrocannabinol, the pharmacologically active cannabinoid in marijuana. Drug discoveries & therapeutics. vol 3. issue 3. 2012-10-02. PMID:22495534. |
studies on tetrahydrocannabinolic acid synthase that produces the acidic precursor of tetrahydrocannabinol, the pharmacologically active cannabinoid in marijuana. |
2012-10-02 |
2023-08-12 |
Not clear |
| F Taur. Studies on tetrahydrocannabinolic acid synthase that produces the acidic precursor of tetrahydrocannabinol, the pharmacologically active cannabinoid in marijuana. Drug discoveries & therapeutics. vol 3. issue 3. 2012-10-02. PMID:22495534. |
tetrahydrocannabinol (thc), the psychoactive component of marijuana, is now regarded as a promising medicine because this cannabinoid has been shown to exert a variety of therapeutic activities. |
2012-10-02 |
2023-08-12 |
Not clear |
| Radu Tanasescu, David Rog, Cris S Constantinesc. A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'. Expert opinion on drug discovery. vol 6. issue 4. 2012-10-02. PMID:22646020. |
although the cannabis sativa herb has been known for its therapeutic benefit for centuries, the interest in the clinical potential of cannabinoid-based drugs escalated after the discovery of the endocannabinoid system. |
2012-10-02 |
2023-08-12 |
Not clear |
| David M Schwope, Wendy M Bosker, Johannes G Ramaekers, David A Gorelick, Marilyn A Huesti. Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. Journal of analytical toxicology. vol 36. issue 6. 2012-10-01. PMID:22589524. |
these data inform our understanding of impairment and subjective effects following acute smoked cannabis and interpretation of whole blood cannabinoid concentrations in forensic investigations. |
2012-10-01 |
2023-08-12 |
Not clear |
| Antonio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, José Alexandre S Cripp. Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology. vol 219. issue 1. 2012-09-20. PMID:21947314. |
interaction between cannabidiol (cbd) and ∆(9)-tetrahydrocannabinol (thc): influence of administration interval and dose ratio between the cannabinoids. |
2012-09-20 |
2023-08-12 |
Not clear |
| Sean D McAllister, Ryuichi Murase, Rigel T Christian, Darryl Lau, Anne J Zielinski, Juanita Allison, Carolina Almanza, Arash Pakdel, Jasmine Lee, Chandani Limbad, Yong Liu, Robert J Debs, Dan H Moore, Pierre-Yves Despre. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast cancer research and treatment. vol 129. issue 1. 2012-09-14. PMID:20859676. |
we previously reported that cannabidiol (cbd), a cannabinoid with a low toxicity profile, down-regulated id-1 gene expression in aggressive human breast cancer cells in culture. |
2012-09-14 |
2023-08-12 |
mouse |
| Verena Isabell Leussink, Leila Husseini, Clemens Warnke, Erasmia Broussalis, Hans-Peter Hartung, Bernd C Kieseie. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Therapeutic advances in neurological disorders. vol 5. issue 5. 2012-09-14. PMID:22973422. |
recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with ms. based on these data, nabiximols (sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned cannabis sativa chemovars, received approval for treating ms-related spasticity in various countries around the globe. |
2012-09-14 |
2023-08-12 |
Not clear |